Eli Lilly

News

The pricing agreement between Novo Nordisk and Eli Lilly and the Trump administration on GLP-1 drugs for diabetes and obesity has arrived.

News

Eli Lilly has raised the stakes in the obesity market with positive midstage data for its amylin-targeting drug eloralintide.

News

After so many announcements of new facility builds in the US, Eli Lilly has made a welcome commitment to a European investment.

News

Eli Lilly is celebrating a massive 54% increase in its third-quarter revenues to $17.6 billion, driven by its medicines for diabetes and obesity.

News

Eli Lilly and NVIDIA have joined forces on an ambitious plan – building pharma's most powerful AI-powered supercomputer for drug discovery.

News

Innovent's dual glucagon and GLP-1 agonist mazdutide outperforms Novo Nordisk's Ozempic in overweight people with diabetes.